How India Exports Prednisolone to the World

Prednisolone, a corticosteroid used to treat various inflammatory and autoimmune conditions, has a well-established presence in the U.S. pharmaceutical market. The FDA has approved numerous Abbreviated New Drug Applications (ANDAs) for prednisolone formulations, indicating a competitive generic landscape. For instance, Halsey Drug's ANDA #040287 for prednisolone was approved on May 28, 1999. Additionally, Taro Pharmaceuticals received approval for Flo-Pred (prednisolone acetate oral suspension) under NDA #022067 on January 17, 2008.

The regulatory pathway for prednisolone involves demonstrating bioequivalence to the reference listed drug, as per FDA guidelines. Given the substantial number of active Indian exporters (755) supplying prednisolone to the U.S., compliance with FDA regulations, including Good Manufacturing Practices (GMP) and potential inspections, is critical to maintain market access.

In the European Union and the United Kingdom, prednisolone is subject to stringent regulatory oversight. Marketing authorizations are granted by the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Manufacturers must adhere to EU Good Manufacturing Practice (GMP) standards to ensure product quality and safety. Notably, on December 15, 2025, the MHRA issued a Class 3 medicines recall for Activase Pharmaceuticals Limited's Prednisolone 5mg Soluble Tablets due to reports of blister pockets becoming swollen over time. (gov.uk)

Prednisolone is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in global health. The drug is also subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, prednisolone is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, prednisolone is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with international standards and regulations.

Prednisolone's primary patents have long expired, leading to a robust generic market with significant competition. This competitive environment is reflected in the substantial number of active Indian exporters (755) and the diverse range of destination countries (182) for prednisolone exports.

In December 2025, the MHRA issued a Class 3 medicines recall for Activase Pharmaceuticals Limited's Prednisolone 5mg Soluble Tablets due to reports of blister pockets becoming swollen over time. (gov.uk)

In January 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the marketing authorization for Akeega, indicating its use with prednisone or prednisolone for specific prostate cancer treatments. (ema.europa.eu)

These developments highlight the dynamic regulatory environment surrounding prednisolone and its formulations, emphasizing the need for manufacturers and exporters to stay informed and compliant with evolving standards and requirements.

India's pharmaceutical industry, including the production of Prednisolone, has historically relied on China for Key Starting Materials (KSMs) and intermediates. This dependency has exposed the supply chain to vulnerabilities, particularly when Chinese manufacturers faced shutdowns due to environmental regulations, leading to supply disruptions and cost escalations.

In response, the Indian government introduced the Production Linked Incentive (PLI) scheme to bolster domestic API and KSM manufacturing, aiming to reduce reliance on imports. This initiative has led to increased local production capacity and technological advancements, enhancing supply chain resilience. (pharmanow.live)

Our data indicates that the top five exporters of Prednisolone from India account for 45.8% of total exports, with STRIDES PHARMA SCIENCE LIMITED leading at an 11.1% share. This concentration suggests a moderate risk of supply disruption if any of these key suppliers face operational challenges.

The PLI scheme has incentivized diversification by supporting a broader base of manufacturers, thereby mitigating single-source risks. However, the effectiveness of this diversification in the Prednisolone supply chain requires ongoing assessment.

Recent geopolitical tensions, notably the closure of the Strait of Hormuz in early 2026, have disrupted global supply chains, including pharmaceutical exports from India. This closure has led to increased shipping costs and delays, impacting the timely delivery of Prednisolone to key markets.

Additionally, instability in the Red Sea region has further complicated shipping routes, necessitating longer transit times and higher fuel costs. These disruptions underscore the need for robust contingency planning within the supply chain. (pharmasource.global)

• Diversify Supplier Base: Encourage partnerships with multiple API and KSM suppliers, both domestically and internationally, to reduce dependency on a single source.

• Enhance Domestic Production: Leverage government incentives like the PLI scheme to strengthen local manufacturing capabilities for APIs and KSMs.

• Develop Alternative Shipping Routes: Identify and establish alternative logistics pathways to circumvent geopolitical hotspots, ensuring uninterrupted supply chains.

• Increase Inventory Buffers: Maintain strategic stockpiles of critical materials to cushion against supply chain disruptions.

• Implement Advanced Monitoring Systems: Utilize real-time tracking and predictive analytics to anticipate and respond swiftly to potential disruptions.

RISK_LEVEL: MEDIUM